Columbia University

Technology Ventures

Human antibodies for immunohistochemical analysis of prostate cancer

Technology #2739

This technology describes polyclonal antibodies for immunohistochemical analysis of prostate carcinoma tissues.

Unmet Need: Improved detection of prostate cancer

Early detection of prostate cancer is key to successful treatment. Current methods for detection of cancer typically require a physical exam or the detection of prostate-specific antigen (PSA) in the blood. However, a biopsy is often still needed to confirm diagnosis and determine treatment options. As such, there is a need for targeted antibodies for immunohistochemical analysis that can diagnose and classify prostate cancer for personalized treatment.

The Technology: Human anti-Nkx3.1 antibodies enable detection of cancer in prostate tissue

This technology provides polyclonal antibodies against the Nkx3.1 homeobox gene product for targeted detection and analysis of prostate carcinoma tissues. Loss of function of NKx3.1 in mice is associated with loss of function of the Pten tumor suppressor gene linked to cancer progression. Consequently, the absence of NKx3.1 protein expression may indicate early human prostate carcinogenesis and could be employed as a diagnostic test for prostate cancer. This technology provides antibodies against Nkx3.1 that could be used for diagnosing loss of NKx3.1 expression in immunohistochemical analysis or other bioassays.


  • Immunohistochemical analysis of prostate carcinomas
  • Detection and characterization of prostate cancer


  • Provides a direct assay against the Nkx3.1 protein involved in cancer initiation
  • Compatible with existing immunohistochemical methods

Lead Inventor:

Cory Abate-Shen, Ph.D.

Patent Information:

Related Publications:

Tech Ventures Reference: